ACTRN12613000297729终止1 期
A Phase 1/2 study to determine the effect of EGFR targeted Doxorubicin loaded EnGeneIC Delivery Vehicles (VEDVDox) on progression free survival in Patients with Recurrent Glioblastoma Multiforme (GBM) Expressing Epidermal Growth Factor Receptor (EGFR)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- EnGeneIC Ltd
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients with pathologically documented, and definitively diagnosed recurrent WHO Grade IV advanced malignant GBM which expresses EGFR.
排除标准
- •Previous treatment with bevacizumab or anti-angiogenic therapy, treatment with immunotherapeutic agents, vaccines, or monoclonal antibody in past 4 weeks. Known allergy or sensitivity to any of the excipients in the investigational product
研究者
相似试验
已完成
不适用
Study of association between effect of first EGFR-TKI for EGFR-mutated non-small cell lung cancer and circulating tumor DNA detected with high sensitive analyses for EGFR mutation.non-small cell lung cancerJPRN-UMIN000014092Miyagi CancerCenter30
Unknown
2 期
Panitumumab Skin Toxicity Prevention TrialColorectal Cancer MetastaticSkin ToxicityNCT03167268Ospedale San Carlo Borromeo28
进行中（未招募）
1 期
An interventional study of oral EGF816 in adult patients with EGFRmut solid malignanciesSolid tumorsMedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2013-004482-14-DEovartis Pharma Services AG500
进行中（未招募）
1 期
An interventional study of oral EGF816 in adult patients with EGFRmut solid malignanciesSolid tumorsMedDRA version: 17.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2013-004482-14-ESovartis Farmacéutica, S.A.211
进行中（未招募）
1 期
An interventional study of oral EGF816 in adult patients with EGFRmut solid malignanciesSolid tumorsMedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2013-004482-14-NLovartis Pharma Services AG211